-
1.发明申请公开(公告)号：US20080085862A1
公开(公告)日：2008-04-10
申请号：US11744162
申请日：2007-05-03
CPC分类号： A61K47/68 , A61K47/6811 , A61K47/6813 , A61K47/6835 , C07K14/505 , C07K14/535 , C07K14/56 , C07K14/61 , C07K16/46 , C07K19/00 , C07K2317/52 , C07K2317/732 , C07K2317/734 , C07K2319/30
摘要： The present invention relates to an Natriuretic peptide conjugate having improved in-vivo duration of efficacy and stability, comprising an Natriuretic peptide, a non-peptidyl polymer and a carrier substance, which are covalently linked to each other, and a use of the same. The Natriuretic peptide conjugate of the present invention has the in-vivo activity which is maintained relatively high, and has remarkably increased blood half-life, and thus it can be desirably employed in the development of long-acting formulations of various peptide drugs.
摘要翻译： 本发明涉及具有改善的功效和稳定性的体内持续时间的利尿钠肽缀合物，其包含彼此共价连接的利尿钠肽，非肽基聚合物和载体物质及其用途。 本发明的利钠肽结合物具有保持较高的体内活性，并且具有显着增加的血液半衰期，因此可以理想地用于开发各种肽药物的长效制剂。
-
2.发明申请Peg-physiologically active polypeptide homodimer complex having prolonged in vivo half-life and process for the preparation thereof 审中-公开具有延长的体内半衰期的Peg生理活性多肽同二聚体复合物及其制备方法公开(公告)号：US20060276586A1
公开(公告)日：2006-12-07
申请号：US10551764
申请日：2004-04-03
CPC分类号： C07K14/475 , A61K47/60 , C07K14/53 , C07K14/56 , C07K14/575 , C07K14/61 , C07K2319/00
摘要： A PEG-polypeptide homodimer complex, which comprises a PEG linker and two molecules of a physiologically active polypeptide, wherein the two molecules of the physiologically active polypeptide are connected via the PEG linker, and each of the two molecules of the physiologically active polypeptide is modified with one molecule of PEG, is useful for the development of a polypeptide drug having a prolonged half-life in the blood.
摘要翻译： PEG-多肽同二聚体复合物，其包含PEG接头和两个生理活性多肽分子，其中生理活性多肽的两个分子通过PEG接头连接，并且生理活性多肽的两个分子中的每一个被修饰 使用一分子PEG可用于开发血液中具有延长半衰期的多肽药物。
-
3.发明申请Protein complex using an immunoglobulin fragment and method for the preparation thereof 有权使用免疫球蛋白片段的蛋白质复合物及其制备方法公开(公告)号：US20060269553A1
公开(公告)日：2006-11-30
申请号：US10535232
申请日：2004-11-13
IPC分类号： A61K39/395 , C07K16/46 , C12N9/00
CPC分类号： A61K47/68 , A61K47/6811 , A61K47/6813 , A61K47/6835 , C07K14/505 , C07K14/535 , C07K14/56 , C07K14/61 , C07K16/46 , C07K19/00 , C07K2317/52 , C07K2317/732 , C07K2317/734 , C07K2319/30
摘要： Disclosed are a protein conjugate with improved in vivo duration and stability and the use thereof. The protein conjugate includes a physiologically active polypeptide, a non-peptide polymer and an immunoglobulin Fc fragment. Since the three components are covalently linked, the protein conjugate has extended in vivo duration and enhanced stability for the physiologically active polypeptide. The protein conjugate maintains the in vivo activity at relatively high levels and remarkably increases the serum half-life for the physiologically active polypeptide, with less risk of inducing undesirable immune responses. Thus, the protein conjugate is useful for developing long-acting formulations of various polypeptide drugs.
摘要翻译： 公开了具有改善的体内持续时间和稳定性的蛋白质缀合物及其用途。 蛋白质缀合物包括生理活性多肽，非肽聚合物和免疫球蛋白Fc片段。 由于三种成分共价连接，因此蛋白质缀合物延长了生理活性多肽的体内持续时间和增强的稳定性。 蛋白质缀合物以较高的水平保持体内活性，并显着增加生理活性多肽的血清半衰期，具有诱导不良免疫反应的风险较小。 因此，蛋白质缀合物可用于开发各种多肽药物的长效制剂。
-
4.发明申请Pharmaceutical composition comprising an immunoglobulin fc region as a carrier 有权药物组合物，其包含免疫球蛋白fc区域作为载体公开(公告)号：US20060275254A1
公开(公告)日：2006-12-07
申请号：US10535231
申请日：2004-11-13
IPC分类号： A61K39/395 , C07K16/46 , A61K38/19 , A61K38/21
CPC分类号： A61K47/68 , A61K47/6811 , A61K47/6813 , A61K47/6835 , C07K14/505 , C07K14/535 , C07K14/56 , C07K14/61 , C07K16/46 , C07K19/00 , C07K2317/52 , C07K2317/732 , C07K2317/734 , C07K2319/30
摘要： Disclosed is a novel use of an immunoglobulin Fe fragment, and more particularly, a pharmaceutical composition comprising an immunoglobulin Fe fragment as a carrier. The pharmaceutical composition comprising an immunoglobulin Fe fragment as a carrier remarkably extends the serum half-life of a drug while maintaining the in vivo activity of the drug at relatively high levels. Also, when the drug is a polypeptide drug, the pharmaceutical composition has less risk of inducing immune responses compared to a fusion protein of the immunoglobulin Fe fragment and a target protein, and is thus useful for developing long-acting formulations of various polypeptide drugs.
摘要翻译： 公开了免疫球蛋白Fe片段的新用途，更具体地，涉及包含免疫球蛋白Fe片段作为载体的药物组合物。 包含作为载体的免疫球蛋白Fe片段的药物组合物显着延长了药物的血清半衰期，同时保持药物的体内活性在相对较高的水平。 此外，当药物是多肽药物时，与免疫球蛋白Fe片段和靶蛋白质的融合蛋白相比，药物组合物具有较少的诱导免疫应答的风险，因此可用于开发各种多肽药物的长效制剂。
-
5.发明申请公开(公告)号：US20070041967A1
公开(公告)日：2007-02-22
申请号：US10535341
申请日：2004-11-13
IPC分类号： A61K39/395 , C12P21/08 , C07K16/18 , C12N5/06
CPC分类号： A61K47/68 , A61K47/6811 , A61K47/6813 , A61K47/6835 , C07K14/505 , C07K14/535 , C07K14/56 , C07K14/61 , C07K16/46 , C07K19/00 , C07K2317/52 , C07K2317/732 , C07K2317/734 , C07K2319/30
摘要： Disclosed is an IgG Fc fragment useful as a drug carrier. Also, the present invention discloses a recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment, comprising culturing the transformant. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.
摘要翻译： 公开了可用作药物载体的IgG Fc片段。 此外，本发明公开了表达IgG Fc片段的重组载体，用重组载体转化的转化体，以及制备IgG Fc片段的方法，包括培养转化体。 当缀合到某种药物时，IgG Fc片段改善了药物作用的体内持续时间并使药物的体内活性降低最小化。
-
公开(公告)号：US20060276633A1
公开(公告)日：2006-12-07
申请号：US10535312
申请日：2004-11-13
申请人： Sung Jung , Jin Kim , Young Park , Ki-Doo Choi , Se Kwon , Gwan Lee
发明人： Sung Jung , Jin Kim , Young Park , Ki-Doo Choi , Se Kwon , Gwan Lee
CPC分类号： A61K47/68 , A61K47/6811 , A61K47/6813 , A61K47/6835 , C07K14/505 , C07K14/535 , C07K14/56 , C07K14/61 , C07K16/46 , C07K19/00 , C07K2317/52 , C07K2317/732 , C07K2317/734 , C07K2319/30
摘要： Disclosed are a recombinant expression vector comprising a nucleotide sequence encoding an E. coli-derived signal sequence and a nucleotide sequence encoding an immunoglobulin constant region, and a transformant transformed with the expression vector. Also, disclosed is a method of mass-producing an immunoglobulin constant region by culturing the transformant and expressing the immunoglobulin constant region in a water-soluble form.
摘要翻译： 公开了包含编码大肠杆菌来源的信号序列的核苷酸序列和编码免疫球蛋白恒定区的核苷酸序列的重组表达载体和用表达载体转化的转化体。 此外，公开了通过培养转化体并以水溶性形式表达免疫球蛋白恒定区来大规模生产免疫球蛋白恒定区的方法。
-
7.发明申请Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same 有权结晶S-奥美拉唑锶水合物，其制备方法和含有它们的药物组合物公开(公告)号：US20070093533A1
公开(公告)日：2007-04-26
申请号：US11374034
申请日：2006-03-14
IPC分类号： A61K31/4439 , C07D403/02 , C07F3/02
CPC分类号： C07D401/12
摘要： This invention provides a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, theremostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.
摘要翻译： 本发明提供了一种用于预防或治疗胃酸相关疾病的结晶性S-奥美拉唑水合锶，其具有高光学纯度，耐受性，溶解性和不吸湿性，其制备方法和含有该组合物的药物组合物。
-
8.发明申请Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same 失效结晶氯吡格雷萘磺酸盐或其水合物，其制备方法和含有它们的药物组合物公开(公告)号：US20050228012A1
公开(公告)日：2005-10-13
申请号：US10971028
申请日：2004-10-25
申请人： Sangmin Yun , Eun Kim , Hee Kim , Bo Kwon , Cheol Kim , Han Kim , Kwee-Hyun Suh , Gwan Lee
发明人： Sangmin Yun , Eun Kim , Hee Kim , Bo Kwon , Cheol Kim , Han Kim , Kwee-Hyun Suh , Gwan Lee
IPC分类号： A61K31/4365 , A61K31/4743 , C07D495/04 , C07D498/02
CPC分类号： C07D495/04
摘要： A crystalline clopidogrel naphthalenesulfonate or a hydrate thereof, a method for preparing same, and a pharmaceutical composition containing same are provided.
摘要翻译： 提供结晶氯吡格雷萘磺酸盐或其水合物，其制备方法和含有它们的药物组合物。
-
![Method of preparing thieno[3,2-c]pyridine derivatives and intermediates used therein](/abs-image/US/2007/08/23/US20070197789A1/abs.jpg.150x150.jpg)
9.发明申请Method of preparing thieno[3,2-c]pyridine derivatives and intermediates used therein 失效噻吩并[3,2-c]吡啶衍生物及其中使用的方法公开(公告)号：US20070197789A1
公开(公告)日：2007-08-23
申请号：US10598790
申请日：2005-03-03
申请人： Sangmin Yun , Eun Kim , Hee Kim , Tae Ha , Kwee-Hyun Suh , Gwan Lee
发明人： Sangmin Yun , Eun Kim , Hee Kim , Tae Ha , Kwee-Hyun Suh , Gwan Lee
IPC分类号： C07D498/02 , C07D311/94 , C07D333/04
CPC分类号： C07D333/38 , C07D333/12 , C07D333/16 , C07D333/18 , C07D495/04
摘要： Ticlopidine and clopidogrel having high blood platelet aggregation inhibitory and anti-thrombotic activities are simply prepared by reacting a substituted thiophene derivative with a 2-chlorobenzylamine derivative.
摘要翻译： 通过使取代的噻吩衍生物与2-氯苄胺衍生物反应，简单地制备具有高血小板聚集抑制和抗血栓形成活性的噻氯匹定和氯吡格雷。
-
公开(公告)号：US20050245744A1
公开(公告)日：2005-11-03
申请号：US10526158
申请日：2004-07-19
申请人： Young Moon , Dong Kim , Chul-Hyun Park , Kyung Lee , Jae-Cheol Lee , Gwan Lee , Young-Kil Chang
发明人： Young Moon , Dong Kim , Chul-Hyun Park , Kyung Lee , Jae-Cheol Lee , Gwan Lee , Young-Kil Chang
IPC分类号： C07D221/18 , C07J43/00
CPC分类号： C07J43/00
摘要： A method for preparing a 1-androstene derivative which comprises reacting a 2-iodo-androstane derivative with an oxidizing agent while maintaining the pH of the reaction mixture at a specific range gives the 1-androstene derivative with high purity and yield.
摘要翻译： 制备1-雄甾烯衍生物的方法，其包括使2-碘 - 雄甾烷衍生物与氧化剂反应，同时将反应混合物的pH保持在特定范围，得到高纯度和产率的1-雄甾烯衍生物。
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.029 秒)
